Resonance HealthASX:RHT +4.55% EBITDA Margin % is 19.50% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Resonance Health ranks better than 52.1% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Resonance Health's EBITDA for the
six
months ended in Dec. 2025 was A$1.56 Mil. Resonance Health's Revenue for the
six
months ended in Dec. 2025 was A$7.98 Mil. Therefore, Resonance Health's EBITDA margin for the quarter that ended in Dec. 2025 was 19.50%.
Resonance Health (ASX:RHT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Resonance Health EBITDA Margin % Related Terms
Resonance Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Resonance Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Resonance Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Resonance Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a EBITDA Margin % of 19.50% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #320 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 47.9%.
Is Resonance Health's EBITDA Margin % too high?
Resonance Health's current EBITDA Margin % is 19.50%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Resonance Health's value of 19.50% is 91% above this industry median. Based on the distribution chart, Resonance Health ranks #320 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #320 out of 668 companies for EBITDA Margin %. This puts Resonance Health in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Resonance Health's value of 19.50% is 91% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current EBITDA Margin % of 19.50% is 91% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current EBITDA Margin % is 19.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current EBITDA Margin % is 19.50% and 91% above the Healthcare Providers & Services industry median of 10.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current EBITDA Margin % is 19.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 